Expression of HMGN5 in hepatocellular carcinoma and its influence on the growth of hepatocellular carcinoma
10.3760/cma.j.cn101721-20240806-00249
- VernacularTitle:HMGN5在肝癌组织中的表达及对肝癌细胞生长的影响
- Author:
Shoulei REN
1
;
Hongchun LI
;
Wenli CAO
;
Jize SUN
;
Jianwen ZHAO
Author Information
1. 山东省潍坊市阳光融和医院肿瘤二科，潍坊 261205
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
High mobility group nucleosome-binding protein;
HepG2 cell;
HL-7702 cell;
Growth;
Apoptosis
- From:
Clinical Medicine of China
2025;41(2):105-110
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the affection of high mobility group nucleosome-binding protein 5(HMGN5) gene in the hepatocellular cancer tissue and HepG2 cell and its function in the growth of HepG2 cell.Methods:70 Patients with hepatocellular carcinoma who under-went surgical resection and were confirmed by postoperative pathology in Sunshine Union Hospital of Weifang City from January 2017 to June 2020 were selected. Their clinical and pathological data, surgical resection of liver cancer tissue and adjacent normal liver tissue were collected, their survival time were also recorded. The contents of HMGN5 protein in the hepatocellular cancer tissues and adjacent normal liver tissues of 70 patients were detected by immunohistochemistry. Compare the expression of HMGN5 protein in liver cancer tissue and normal liver tissue and the positive expression rate of HMGN5 protein in liver cancer tissues of hepatocellular carcinoma patients with different clinical characteristics, to analyze the relationship between HMGN5 expression and prognosis of patients with hepatocellular carcinoma.The mRNA contents of HMGN5 gene in HepG2 cells and HL-7702 cells were determined by quantitative real time polymerase chain reaction(qRT-PCR) method. After transfectHepG2 cells with HMGN5 shRNA, the proliferation ability of HepG2 cells were evaluated by cell proliferation assay and the cell apoptosis was analyzed by flow cytometry. Measurement data with normal distribution were expressed as ±s, two independent samples t test was used for comparison between groups. Counting data was expressed as n(%), χ2 test was used for comparison between groups. Survival analysis of patients was performed by Kaplan-Meier method. Results:Immunohistochemical tests showed that HMGN5 staining is strong in liver cancer tissue, but weak in normal liver tissue. HMGN5 protein expression was positive in 48 of 70 patients with hepatocellular carcinoma. The positive expression rate of HMGN5 protein in hepatocellular carcinoma tissues of patients with pathological grade 3+4 and clinical stage Ⅲ+Ⅳ was higher than that of patients with grade 1+2 and stage Ⅰ+Ⅱ, respectively. There was no significant difference in cumulative survival rate between HMGN5 positive expression group and HMGN5 negative expression group ( χ2=3.81, P=0.051). The results of qRT-PCR showed that the expression level of HMGN5 mRNA in hepatoma HepG2 cells was higher than that in normal liver HL-7702 cells [(4.51±0.45) vs (1.35±0.27), the difference was statistically significant ( t=10.43, P=<0.001). After 24, 48 and 72h of the HMGN5 gene was knockout, the survival rate of HepG2 hepatoma cells was lower than that of HL-7702 hepatoma cells (all P<0.05) and the apoptosis rate of hepatoma HepG2 cells was higher than that of liver HL-7702 cells [(18.63±1.76)%vs(1.81±0.21)%] ,the difference was statistically significant ( t=16.44, P<0.001). Conclusions:HMGN5 genes and proteins are highly expressed in the hepatocellular cancer tissues and HepG2 cells. HMGN5 gene plays an important role in the growth of hepatocellular cancer and can be used as a potential target of treatment for hepatocellular cancer.
